Fabry Disease

Active Ingredient: Agalsidase beta

Indication for Agalsidase beta

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Agalsidase beta is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency).

For this indication, competent medicine agencies globally authorize below treatments:

1 mg/kg body weight once every 2 weeks

Route of admnistration

Intravenous

Defined daily dose

1 mg per kg of body weight

Dosage regimen

1 mg per kg of body weight once every 14 day(s)

Detailed description

The recommended dose of agalsidase beta is 1 mg/kg body weight administered once every 2 weeks as an intravenous infusion.

The safety and efficacy of Fabrazyme in children aged 0 to7 years have not yet been established. Currently available data are described in sections 5.1 and 5.2 but no recommendation on posology canbe made in children aged 5 to 7 years. No data are available in children 0 to 4 yearsNo dose adjustment is necessary for children 8-16 years

Dosage considerations

The initial infusion rate should be no more than 0.25 mg/min (15 mg/hour) to minimise the potential occurrence of infusion-associated reactions. After patient tolerance is established, the infusion rate may be increased gradually with subsequent infusions.

Active ingredient

Agalsidase beta

Agalsidase beta is a recombinant form of human α-galactosidase A and is produced by recombinant DNA technology using a mammalian Chinese Hamster Ovary (CHO) cell culture. The amino acid sequence of the recombinant form, as well as the nucleotide sequence which encoded it, are identical to the natural form of α-galactosidase.

Read more about Agalsidase beta

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.